ArticleCureus2025
Efavirenz-Induced Hepatitis Mimicking Autoimmune Hepatitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efavirenz is a widely used and effective non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Hepatotoxicity, although recognized, typically occurs early in the course of NNRTI therapy. However, delayed liver injury resembling autoimmune hepatitis is rare. We report a 62-year-old HIV-positive man on long-term efavirenz who developed new, asymptomatic elevations in liver enzymes after years of stable antiretroviral therapy. Work-up revealed elevated levels antinuclear antibodies (ANA) IgG after exclusion of metabolic and viral hepatitis. Although biopsy findings suggested autoimmune hepatitis, the absence of other autoimmune features and the patient's stable HIV control prompted reconsideration of the diagnosis. A multidisciplinary team suspected efavirenz-related liver injury, and the drug was replaced with Raltegravir while the rest of the antiretroviral therapy (ART) regimen was maintained. Immunosuppression was withheld to observe the biochemical response. Following Efavirenz withdrawal, liver enzymes, IgG, and ANA levels normalized, and liver stiffness on FibroScan improved. This case highlights the challenge of distinguishing autoimmune hepatitis from drug-induced liver injury when autoimmune markers are present and emphasizes the importance of considering late ART toxicity, as timely drug withdrawal can lead to full recovery without immunosuppression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.